Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tris-CAR-T Cell Therapy in Newly Diagnosed Glioblastoma
NCT07873996Phase 3Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
A Phase 3 trial of trispecific chimeric antigen receptor T-cell therapy in glioblastoma (GBM), sponsored by Beijing Tiantan Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
trispecific chimeric antigen receptor T-cell therapy
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07873996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07873996.